Antibiotic biotechs often struggle to turn their products into commercial triumphs, and that's certainly been the case for New Haven, Connecticut-based Melinta Therapeutics, which ultimately filed for bankruptcy in late 2019. But Melinta hopes its newly minted drug can become an exception, thanks to a convenience edge over rivals.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,